Premium
Treatment of age‐related macular degeneration after cataract surgery: a study from the Swedish National Cataract and Macula Registers
Author(s) -
Westborg Inger,
Albrecht Susanne,
Granstam Elisabet,
Karlsson Niklas,
Kugelberg Maria,
Lundström Mats,
Montan Per,
Behndig Anders
Publication year - 2021
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/aos.14519
Subject(s) - medicine , macular degeneration , cataract surgery , ophthalmology , visual acuity , cohort , perioperative , surgery
Purpose To characterize pre‐ and perioperative factors associated with treatment for wet age‐related macular degeneration (wet AMD) after cataract surgery. Methods This register‐based cohort study with data from the Swedish National Cataract Register (NCR) and the Swedish Macula Register (SMR) from 2010 to 2017 compared eyes with and without preoperative AMD that had undergone cataract surgery and was subsequently treated for wet AMD to eyes not treated within the study period. All first‐eye surgeries registered in the NCR from 2010 to 2017 and matching eyes found in the SMR that had undergone treatment for wet AMD ≥ 1 year after the cataract procedure were included. Data for cataract surgery date, age and gender, use of a blue‐blocking IOL, preoperative visual acuity, ocular comorbidities, posterior capsule rupture and date of AMD treatment initiation were extracted. Results The only independent factor associated with postoperative treatment of wet AMD in both groups was female gender (67.3% vs. 58.8%, p < 0.001 and 66.4% vs. 60.6%, p = 0.001, respectively). Older age was an independent factor in eyes without preoperative AMD (78.4 ± 6.5 vs. 73.4 ± 9.6 years, p < 0.001). A blue‐blocking IOL appeared to decrease the likelihood of subsequent wet AMD treatment slightly but not statistically significant in eyes with preoperative AMD (52.7% vs. 56.8%, p = 0.110). Conclusions Some factors (female gender, high age) are associated with undergoing subsequent treatment for wet AMD to a higher extent. If the use of a blue‐blocking IOL offers any protection from undergoing AMD treatment after cataract surgery, such an effect must be very small.